03/11/2026
Women's health is an increasingly important frontier for healthcare innovation, with advances in cancer care creating opportunities to improve quality of life for patients across the world.
In a recent feature by BioSpectrum Asia, Racura Oncology CEO & Managing Director Dr Daniel Tillett shares his perspectives on the evolving landscape of women's cancer care, including the importance of addressing the longer-term side effects of current standard of care cancer treatments.
Racura is exploring this through trials of our lead asset RC220, investigating its anticancer potential across multiple indications, as well as its ability to protect against chemotherapy-induced heart damage.
Read the full article: https://www.biospectrumasia.com/analysis/29/28623/rewriting-the-future-of-womens-health.html